Bridge Laboratories

Haijun (Lou) Dong, Ph.D., MBA has been appointed general manager at Bridge Laboratories’ Beijing, China, facility. Prior to joining the company, Dr. Dong served for three years as member of the senior management team and head of DMPK and Drug Safety at Roche’s R&D Center in Shanghai. Dr. Dong established and managed internal and external operations of physicochemical properties, DMPK, bioanalytical chemistry, and toxicology and safety pharmacology.

Dr. Dong has worked at the University of Washington School of Pharmacy, Boehringer Ingelheim Pharmaceuticals, and Roche Preclinical R&D. In 2002, he was a cofounder and general manager of Shanghai Jahwa Pharmaceuticals, a company focused on the development and commercialization of generics and modified-release formulations. During his four-year tenure as general manager, the company received 12 clinical trial and final marketing approvals from China’s SFDA.

“Dr. Dong brings Bridge a wealth of experience in both pharmaceutical R&D and business management,” said Tom Oakley, president and chief executive officer, Bridge Laboratories. “His experience in China and his understanding of building a start up will be instrumental to the success of our China lab.”